ClinicalTrials.gg
CompletedNCT04999527Updated Jul 19, 2022

Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects

A Phase 1 interventional study of DISC-0974 and Placebo in Healthy Volunteer, sponsored by Disc Medicine, Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-19.

Sponsored by Disc Medicine, Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This Phase 1 study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult healthy volunteers.

Read the detailed description

Enrolled participants in this study will receive a single dose of DISC-0974 or a placebo. Samples will be collected to measure how DISC-0974 is processed by the body and how the body responds when exposed to DISC-0974. Participants will receive a single study drug dose on Day 1; and follow-up for 10 weeks (71 days). If an undetectable DISC-0974 blood concentration is observed, the duration of follow-up will be shortened to 7 days thereafter, as feasible.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Disc Medicine, Inc is the lead sponsor of 11 studies on the registry; 5 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (HV only) adults aged 18 to 65 years, inclusive at the time of consent.
  • Body weight ≥50 kg and (BMI) between 18 and 33, inclusive, at Screening.
  • Systolic blood pressure ≤140 mmHg and diastolic blood pressure ≤90 at Screening.
  • No abnormalities as determined by medical history, by results of physical examination, vital signs, and lab tests at Screening.
  • \<450 msec at Screening.
  • Estimated >60 mL/min/1.73m2 based on the 4 parameter MDRD (Modification of Diet in Renal Disease) equation at Screening
  • TSAT ≤30% at Screening, as determined in a fasting morning blood sample (06:00 to 11:00 hours).
  • Hematologic parameters (red blood cell count [RBC], , hematocrit, count, mean corpuscular volume, mean corpuscular hemoglobin concentration), serum iron, and TIBC within normal range and serum ferritin (within normal range and ≥30 ng/mL) at Screening.
  • If a male with female sexual partner(s) of , must agree to use acceptable methods of during the study and through the End of Study (EOS) visit
  • If female, , as defined with at least 12 months natural, spontaneous amenorrhea, or at least 6 weeks following surgical menopause
  • Able to understand and provide written and comply with protocol requirements

Exclusion criteria

Exclusion Criteria:

  • History of anemia or hematologic disorder within 1 year of Screening
  • History of splenectomy
  • Diagnosis or first-degree relative with a diagnosis of hemochromatosis
  • History of diabetes, cardiovascular, hepatic, renal, or malabsorptive disease
  • Vegan or iron-deficient diet within 3 months of Screening
  • Blood transfusion within 1 year of Screening
  • Whole blood donation within 6 months of Screening or plasma donation within 30 days of Screening.
  • A history of alcohol or illicit drug use disorder within 3 years of Screening, as assessed by the Investigator
  • Use of any tobacco- and/or nicotine-containing containing products, including e-cigarettes, vaping products, and nicotine replacement products, within 3 months of Screening
  • Use of multivitamin or iron supplements within 30 days prior to Screening
  • or aspartate aminotransferase (AST) level above the normal range at Screening
  • Positive urine pregnancy test at Screening or Baseline (Day -1).
  • Positive serologic test for surface antigen, antibody, or (HIV) at Screening.
  • Positive urine screen for drugs of abuse or alcohol test on admission to the study center
  • Use of any systemic prescription medication within 14 days of Screening, non-iron containing dietary supplements, or non-prescription drugs within 7 days of dosing.
  • History of a major surgical procedure within 60 days of Screening or planned surgical procedure within 90 days of dosing.
  • A history or known allergic reaction to any product or history of anaphylaxis to any food or drug.
  • History or presence or any illness that, in the opinion of the Investigator, would interfere with the ability to provide or comply with study instructions.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Healthy Volunteer: Single Ascending Dose of DISC-0974

    Single Intravenous (IV) or Subcutaneous (SC) ascending dose in healthy volunteers

    Drug: DISC-0974

  • Experimental
    Healthy Volunteer: Single Ascending Dose of Placebo

    Single Intravenous (IV) or Subcutaneous (SC) ascending dose in healthy volunteers

    Drug: Placebo

Interventions

  • DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose

  • DrugPlacebo

    Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Time frame: Up to 71 days of monitoring

  2. Incidence of abnormal laboratory test results

    Time frame: Up to 71 days of monitoring

  3. Incidence of treatment-emergent clinically abnormal electrocardiogram (ECG)

    Time frame: Up to 71 days of monitoring

  4. Incidence of treatment-emergent clinically abnormal physical exam

    Time frame: Up to 71 days of monitoring

Secondary outcomes

  1. Plasma maximum measured drug concentration (Cmax)

    Time frame: Up to 71 days of testing

  2. Time of maximum concentration (Tmax)

    Time frame: Up to 71 days of testing

  3. Area under the concentration-time curve (AUC)

    Time frame: Up to 71 days of testing

  4. Plasma half-life (T½)

    Time frame: Up to 71 days of testing

07

Study locations

1 site
  • Worldwide Clinical Trials
    San Antonio, Texas 78217, United States
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Jun 2022, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2021
First posted
Aug 11, 2021
StartActual
Aug 10, 2021
Primary completionActual
Jun 30, 2022
CompletionActual
Jun 30, 2022
Last update
Jul 19, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04999527
Lead sponsor
Disc Medicine, Inc
Responsible party
Sponsor
First posted
Aug 11, 2021
Start date
Aug 10, 2021
Primary completion
Jun 30, 2022
Completion
Jun 30, 2022
Last update
Jul 19, 2022

Study contacts

William Savage, MD, PhD
study director · Disc Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selcodebart

Start the discussion